Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Business Wire•19/10/2026•07:00 ET
0
Key Highlights
- ➤Summit Therapeutics (SMMT) opens global Phase II study of ivonescimab-based regimens in advanced ccRCC
- ➤Approximately 100 previously untreated advanced ccRCC patients planned across U.S. and China
- ➤Four-arm trial evaluates ivonescimab combinations, monotherapy, and nivolumab plus ipilimumab
- ➤Akeso collaboration expands ivonescimab development beyond lung cancer into renal cell carcinoma
- ➤Summit’s additional Arcus collaboration evaluates ivonescimab plus casdatifan in a similar ccRCC setting
Expert Statements
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“In collaboration with Akeso, SMT112-216 reflects an important part of our shared strategy to evaluate ivonescimab across multiple treatment approaches, including combination regimens, in tumor types where meaningful unmet needs remain”
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“Ivonescimab’s dual targeting of PD-1 and VEGF is especially relevant in renal cell carcinoma, where both pathways have been shown to be valid targets to impact the course of the disease”
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC
Get started
Create a free account to read the full story.